The company, which received the license to grow and sell weed from the DEA and DOJ, just raised $20 million

Biopharmaceutical Research Company (BRC), a Monterey, California-based organization that holds a valid Drug Enforcement Administration (DEA) pharmaceutical cannabis license, raised a total of $20 million in Series A funding. Achari Ventures, Argonautic Ventures, AFI Capital Partners, Self Health America, Delta Emerald Ventures and several respected private equity firms participated in the round, which was led by Intrinsic Capital Partners.

As a result, the company will be able to aggressively expand its operations, expand its product line, engage in sponsored research and execute its go-to-market plan.

Biopharmaceutical Research Company quickly expanded its research capabilities, expanded its cannabis cultivation business and developed innovative cannabis-derived products in a manner that complied with federal regulations after receiving DEA Schedule I registration in 2021. According to George Hodgin, BRC CEO, “This tremendous additional financial investment will further enhance the company’s ability to grow as an organization and position BRC as a market leader.”

Intrinsic not only gives BRC the money needed to play snowball games, but also brings a wealth of knowledge about the pharmaceutical industry. George Hodgin added that BRC is incredibly grateful to the Intrinsic team and all of their collaborators for understanding the significant potential of our project.

BRC was a select American company that received a manufacturing license from the DEA in 2021 to produce safe, reliable and legal cannabinoids for nationally recognized researchers. BRC has partnered with university research institutions such as the University of California-Davis and Washington State University.

according to dr Howard Goodwin, Managing Partner of Intrinsic, BRC has the tremendous potential that the fund is looking for in a company. Howard added that Intrinsic Capital Partners is excited to be working with a company that is already in a favorable position due to its unique ability to fully comply with the DEA. You are a purpose driven company with strong management in a high growth market.

Biopharmaceutical research company team

BRC enters its Series A investment round with a solid and experienced team and is pleased to announce the addition of PIPV Capital’s Senior Managing Partner and owner of GlaxoSmithKline Ventures, Osagie Imasogie, to its Board of Directors. In addition, BRC welcomes former Massachusetts Cannabis Control Commission Chair Steven Hoffman and Bob Sheriff, former Global Head of Supply Chain for numerous companies at Johnson & Johnson, to its Advisory Board. Image and Sheriff are both members of Intrinsic’s extensive operating network.

Hunter Land has been appointed Vice President of Translational Research as the BRC workforce continues to grow. Land was formerly the vice president of translational research and an executive board member at Alterola Biotech. He has over 18 years of R&D experience across 15 different indications and 10 years of experience in cannabinoid-focused research. As a specialist in the field of cannabinoid science, he has produced a number of research papers on more than 20 novel terpenes and cannabinoids.

About the Biopharmaceutical Research Company (BRC)

The Biopharmaceutical Research Company (BRC), led by CEO George Hodgin, is a DEA-registered botanical cannabis company focused on federally authorized manufacturing of active pharmaceutical ingredients and collaborative research and development.

The company’s goal is to provide researchers and patients worldwide with high-quality, government-approved pharmaceutical active ingredients for herbal medicines. BRC has recently collaborated with university research institutes such as the University of California-Davis and Washington State University.

They can do all API botanical activities because they are a certified, government-authorized cannabis pharmaceutical company. They will also sponsor the Investigational New Drug (IND) proposals of many investigators to pursue cures for chronic pain, PTSD and other conditions.

equity partner

Intrinsic Capital Partners is a Pennsylvania-based investment firm specializing in life science and technology companies in the legal hemp and cannabis industries. The Intrinsic team combines institutional investment discipline with world-class operational experience to create and scale industry-leading companies that address neglected needs across the supply chain.

Intrinsic Capital Partners is a private equity investment firm investing in promising, growing companies in the legal cannabis market. Their team has extensive investment, regulatory, pharma and transaction structure experience. They seek to create value for portfolio company owners and provide our fund investors with superior returns in collaboration with our world-class ecosystem of operating partners with years of experience in establishing brands and companies in the healthcare and consumer goods industries.

Intrinsic Capital Partners offers an operator-centric investment methodology to build a comprehensive portfolio of quality cannabis and hemp companies. North Point Mergers and Acquisitions acted as BRC’s private placement agent on the fundraiser and Morrison & Foerster LLP acted as legal counsel.

The Drug Enforcement Agency

The Drug Enforcement Administration (DEA) is a federal law enforcement agency of the United States Department of Justice charged with combating drug trafficking in the United States. It is the primary enforcement agency for the Controlled Substances Act in the United States, sharing powers with the US Customs and Border Protection, the Federal Bureau of Investigation, the US Customs Service and the US Immigration Service. The DEA is primarily responsible for coordinating and pursuing U.S. drug prosecutions at the international and domestic levels.

The DEA maintains a registration system that allows anyone to manufacture, export, import, and market Schedule I drugs by submitting the DEA Form 225. and 5 if licensed by the DEA. Authorized applicants apply for and receive a “DEA number”.

A DEA number authorizes an entity to manufacture (drug companies), distribute, prescribe (including but not limited to nurses, pharmacists, physicians, and physician assistants), research, or dispense (pharmacy) a prohibited substance. BRC was a select American company that received a manufacturing license from the DEA in 2021 to produce safe, reliable and legal cannabinoids for nationally recognized researchers.

Conclusion

The recent $20 million in funding allows the Biopharmaceutical Research Company to rapidly expand its research capabilities, enhance its cannabis cultivation business and develop innovative cannabis-derived products that comply with federal regulations.

MORE ABOUT BRC, READ MORE…

THE DEA JUST AWARDED SOMEONE A FEDERAL MARIJUANA LICENSE!